The National Institute of Mental Health is offering a grant to accelerate drug and device discovery for the treatment of mental health, substance use disorders, and alcohol use disorder. This grant aims to support innovative research in developing and validating tools, conducting early-stage human studies, and advancing preclinical development of new candidate agents and neurostimulation approaches. Partnerships between academia and industry are highly encouraged. The closing date for application submission is March 25, 2022.
Opportunity ID: 324841
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-119 |
| Funding Opportunity Title: | National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U19 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 25, 2020 |
| Last Updated Date: | Feb 25, 2020 |
| Original Closing Date for Applications: | Mar 25, 2022 |
| Current Closing Date for Applications: | Mar 25, 2022 |
| Archive Date: | Apr 30, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Independent school districts Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments For profit organizations other than small businesses Public and State controlled institutions of higher education Small businesses State governments Native American tribal governments (Federally recognized) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this FOA is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, SUDs or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, SUDs or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-119.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 324841 Full Announcement-PAR-20-119 -> PAR-20-119-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00258916 | Feb 25, 2020 | Jan 24, 2022 | View | |
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00258584 | Feb 25, 2020 | May 24, 2020 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00269639 | Oct 27, 2021 | Mar 25, 2022 | View |
Package 1
Mandatory forms
324841 RR_SF424_2_0-2.0.pdf
324841 PHS398_CoverPageSupplement_5_0-5.0.pdf
324841 RR_OtherProjectInfo_1_4-1.4.pdf
324841 PerformanceSite_2_0-2.0.pdf
324841 RR_KeyPersonExpanded_2_0-2.0.pdf
324841 PHS398_ResearchPlan_4_0-4.0.pdf
324841 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
324841 PHS_Additional_IndirectCosts-1.0.pdf
324841 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
324841 RR_SF424_2_0-2.0.pdf
324841 PHS398_CoverPageSupplement_4_0-4.0.pdf
324841 RR_OtherProjectInfo_1_4-1.4.pdf
324841 PerformanceSite_2_0-2.0.pdf
324841 RR_KeyPersonExpanded_2_0-2.0.pdf
324841 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
324841 PHS_Additional_IndirectCosts-1.0.pdf
324841 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 3
Mandatory forms
324841 RR_SF424_5_0-5.0.pdf
324841 PHS398_CoverPageSupplement_5_0-5.0.pdf
324841 RR_OtherProjectInfo_1_4-1.4.pdf
324841 PerformanceSite_4_0-4.0.pdf
324841 RR_KeyPersonExpanded_4_0-4.0.pdf
324841 PHS398_ResearchPlan_4_0-4.0.pdf
324841 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
324841 PHS_Additional_IndirectCosts_2_0-2.0.pdf
324841 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
